Đang chuẩn bị liên kết để tải về tài liệu:
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: Activity and safety results from a phase II study
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
This phase II study evaluated the efficacy and safety/tolerability of sunitinib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC). Methods: Eligible patients received sunitinib 37.5 mg/day and trastuzumab administered either weekly (loading, 4 mg/kg; then weekly 2 mg/kg) or 3-weekly (loading, 8 mg/kg; then 3-weekly 6 mg/kg). Prior trastuzumab and/or lapatinib treatment were permitted. The primary endpoint was objective response rate (ORR). |